OBJECTIVES: The purpose of this systematic review was to assess the efficacy of growth hormone (GH) treatment in patients with short bowel syndrome (SBS). METHODS: Electronic searches were performed to identify all publications describing randomized controlled trials (RCTs) on the use of GH with or without glutamine for the treatment of patients with SBS. The outcomes of interest were body weight, lean body mass, and intestinal absorption function. RESULTS: Four trials involving 70 patients were included in the review. A meta-analysis of these trials suggested that GH had a positive effect in terms of increased weight (mean difference [MD] = 1.66; 95% CI, 0.69-2.63, P < 0.001), lean body mass (MD = 1.93; 95% CI, 0.97-2.90; P < 0.001), energy absorption (MD = 4.42; 95% CI, 0.26-8.58; P = 0.04), nitrogen absorption (MD = 4.85; 95% CI, 0.20-9.49; P = 0.04), and fat absorption (MD = 5.02; 95% CI, 0.21-9.82; P = 0.04) for patients with SBS. Adverse effects occurred during active treatment in all trials. Only 1 trial included a 12-week follow-up study. CONCLUSIONS: The results suggest a possible short-term benefit in terms of body weight, lean body mass, and absorptive capacities; however, no conclusion of long-term efficacy of GH could be obtained. Large-scale, long-term follow-up RCTs are needed to confirm the efficacy and tolerability of GH in the future.
OBJECTIVES: The purpose of this systematic review was to assess the efficacy of growth hormone (GH) treatment in patients with short bowel syndrome (SBS). METHODS: Electronic searches were performed to identify all publications describing randomized controlled trials (RCTs) on the use of GH with or without glutamine for the treatment of patients with SBS. The outcomes of interest were body weight, lean body mass, and intestinal absorption function. RESULTS: Four trials involving 70 patients were included in the review. A meta-analysis of these trials suggested that GH had a positive effect in terms of increased weight (mean difference [MD] = 1.66; 95% CI, 0.69-2.63, P < 0.001), lean body mass (MD = 1.93; 95% CI, 0.97-2.90; P < 0.001), energy absorption (MD = 4.42; 95% CI, 0.26-8.58; P = 0.04), nitrogen absorption (MD = 4.85; 95% CI, 0.20-9.49; P = 0.04), and fat absorption (MD = 5.02; 95% CI, 0.21-9.82; P = 0.04) for patients with SBS. Adverse effects occurred during active treatment in all trials. Only 1 trial included a 12-week follow-up study. CONCLUSIONS: The results suggest a possible short-term benefit in terms of body weight, lean body mass, and absorptive capacities; however, no conclusion of long-term efficacy of GH could be obtained. Large-scale, long-term follow-up RCTs are needed to confirm the efficacy and tolerability of GH in the future.
Authors: Stephen J D O'Keefe; Alan L Buchman; Thomas M Fishbein; Khursheed N Jeejeebhoy; Palle Bekker Jeppesen; Jonathan Shaffer Journal: Clin Gastroenterol Hepatol Date: 2006-01 Impact factor: 11.382
Authors: J S Scolapio; M Camilleri; C R Fleming; L V Oenning; D D Burton; T J Sebo; K P Batts; D G Kelly Journal: Gastroenterology Date: 1997-10 Impact factor: 22.682
Authors: R R van der Hulst; B K van Kreel; M F von Meyenfeldt; R J Brummer; J W Arends; N E Deutz; P B Soeters Journal: Lancet Date: 1993-05-29 Impact factor: 79.321
Authors: T A Byrne; T B Morrissey; T V Nattakom; T R Ziegler; D W Wilmore Journal: JPEN J Parenter Enteral Nutr Date: 1995 Jul-Aug Impact factor: 4.016
Authors: Minna M Wieck; Christopher R Schlieve; Matthew E Thornton; Kathryn L Fowler; Mubina Isani; Christa N Grant; Ashley E Hilton; Xiaogang Hou; Brendan H Grubbs; Mark R Frey; Tracy C Grikscheit Journal: Cell Mol Gastroenterol Hepatol Date: 2017-01-24